CAJ | 학술논문

目的：探讨重组人血管内皮抑制素和培美曲塞+顺铂联合治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法：选取2010年1月-2012年1月笔者所在医院收治的晚期NSCLC患者76例，随机分为观察组和对照组，每组38例，对照组仅给予培美曲塞+顺铂化疗，观察组在上述治疗基础上给予重组人血管内皮抑制素(恩度)治疗，观察并比较两组患者临床疗效及不良反应发生情况。结果：观察组临床总有效率、临床获益率均明显高于对照组(P<0.05)。观察组患者1年生存率和中位疾病进展时间均明显高于对照组，差异均有统计学意义(P<0.05)。结论：重组人血管内皮抑制素联合培美曲塞+顺铂治疗晚期非小细胞肺癌的临床疗效显著，不良反应小，患者临床收益率高，可在临床推广应用。
목적：탐토중조인혈관내피억제소화배미곡새+순박연합치료만기비소세포폐암(NSCLC)적림상료효。방법：선취2010년1월-2012년1월필자소재의원수치적만기NSCLC환자76례，수궤분위관찰조화대조조，매조38례，대조조부급여배미곡새+순박화료，관찰조재상술치료기출상급여중조인혈관내피억제소(은도)치료，관찰병비교량조환자림상료효급불량반응발생정황。결과：관찰조림상총유효솔、림상획익솔균명현고우대조조(P<0.05)。관찰조환자1년생존솔화중위질병진전시간균명현고우대조조，차이균유통계학의의(P<0.05)。결론：중조인혈관내피억제소연합배미곡새+순박치료만기비소세포폐암적림상료효현저，불량반응소，환자림상수익솔고，가재림상추엄응용。
Objective:To investigate the clinical efficacy of Recombinant Human Endostatin combined with Pemetrexed and Cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC).Method:76 patients with advanced NSCLC in our hospital were randomly divided into the observation group and the control group,38 cases in each group.The cases in the control group only received Pemetrexed and Cisplatin,while the cases in the observation group received administration of Recombinant Human Endostatin treatment on the basis of the above.The clinical efficacy and adverse events of two groups were observed and compared.Result:The total clinical efficiency and clinical benefit rate of the observation group were significantly higher than those of the control group(P<0.05). 1-year survival and median time to progression of the observation group were significantly higher than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The clinical efficacy of Recombinant Human Endostatin combined with Pemetrexed and Cisplatin in the treatment of advanced non-small cell lung cancer are significant,less side effects,which can be applied in clinic.